Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04503122
Other study ID # BARO-AF
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 12, 2021
Est. completion date October 1, 2022

Study information

Verified date January 2021
Source Poitiers University Hospital
Contact Rodrigue Garcia
Phone +33549453729
Email sec.rythmologie@chu-poitiers.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Atrial fibrillation is the most common arrhythmia. The posterior surface of the left atrium is covered by an extensive network belonging to the autonomic nervous system that can be damaged during the ablation. The involvement of the autonomous nervous system in the genesis and maintenance of atrial fibrillation remains poorly understood. Baroreflex sensitivity is a non-invasive method assessing autonomous nervous system activity. The rate of atrial fibrillation recurrence after ablation is currently high and a better understanding of the mechanisms associated with recurrence is essential to improve selection of the patients who will benefit the most from this procedure. The aim of this study is to evaluate the association between the baroreflex sensitivity and atrial fibrillation recurrences and to analyze the prognostic contribution of the baroreflex measurement compared to other published criteria.


Recruitment information / eligibility

Status Recruiting
Enrollment 116
Est. completion date October 1, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Age = 18 years old, - Patients with paroxysmal atrial fibrillation, hospitalized for atrial fibrillation ablation, - Assessable baroreflex sensitivity before ablation, - Free subject, without guardianship or curatorship or subordination, - Patients benefiting from a Social Security assurance, - Informed consent signed by the patient after clear and fair information about the study. Exclusion Criteria: - Age < 18, - History of atrial fibrillation ablation, - Inability to calculate the baroreflex sensitivity - Contraindication to the performance of a cardiac CT scan (allergy to iodine, severe renal insufficiency with clearance <30 ml/mn/m2), - Inability to have continuous ECG recording by subcutaneous Holter,

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
pulmonary vein isolation
pulmonary vein isolation : cryoablation or radiofrequency

Locations

Country Name City State
France CHU de Poitiers Poitiers

Sponsors (1)

Lead Sponsor Collaborator
Poitiers University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean slope assessed before ablation in the recurrence and the non-recurrence groups To compare baroreflex sensitivity assessed by mean Slope 1 month before the ablation in the recurrence group at 1 year and in the no AF recurrence group at 1 year. Recurrence is assessed at one year of follow-up
Secondary Association between baroreflex sensitivity assessed before ablation and atrial fibrillation burden Association between baroreflex sensitivity evaluated by mean slope, LF gain and HF gain 1 month before AF ablation and AF burden after 1 year of follow-up; Burden is assessed at one year of follow-up
Secondary Baroreflex sensitivity fall between the groups with and without AF recurrence To compare the baroreflex sensitivity fall between before and day1 of ablation between the groups with and without AF recurrence at 1 year follow-up ; Recurrence is assessed at one year of follow-up
Secondary Evolution of baroreflex sensitivity To describe the evolution of baroreflex sensitivity in the group with and in the group without recurrence. Before, day 1 and month 3 after the ablation
Secondary Biological and imaging parameters To look for an association between biological and imaging parameters and atrial fibrillation burden at 1 year. Burden is assessed at one year of follow-up
Secondary Quality of life To compare quality of life before and at one year after atrial fibrillation ablation in patients with and without AF recurrence; before and at one year after atrial fibrillation ablation
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05534581 - SINGLE SHOT CHAMPION Phase 4
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed NCT00964392 - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Phase 4